The study of the effectiveness and safety of the use of Mexidol and Mexidol Forte 250 in patients with chronic brain ischemia

Author:
V.A. Kutashov, O.V. Ulyanova

FSBEI in Voronezh State Medical University named after N.N. Burdenko »Ministry of Health of Russia, Voronezh, Russia

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2019, T. 119, No. 12, Issue. 2

Summary:
Purpose of the study. The study of the effectiveness and safety of therapy with Mexidol, prescribed intravenously (500 mg 1 time per day) for 14 days, followed by the oral administration of Mexidol Forte 250 in 250 mg 3 times a day in patients with chronic brain ischemia (chemical). Material and methods. The study includes 56 patients with chemicals, which developed against the background of a combination of arterial hypertension and atherosclerosis. They evaluated the results of physical examination methods (level of blood pressure, heart rate, etc.), complaint dynamics, indicators on the scales of the general clinical impression (CGI), Mosa, asthenia MFI 20, anxiety and depression of Hamilton, Tinnetti. Results and conclusion. The results of the study showed the effectiveness and safety of intravenous administration of Mexidol, followed by the oral administration of Mexidol Forte 250. The specified scheme of therapy contributed to the regression of objective and subjective symptoms of HIM, and led to improvement in the emotional, cognitive and motor spheres. Key words: chronic brain ischemia, atherosclerosis, arterial hypertension, motor disorders, cognitive disorders, Mexidol, Mexidol Fort 250.